Oct 16, 2026 02:53AM
Oct 6, 2026 07:40AM
Sep 1, 2026 04:23AM
Aug 4, 2026 06:00AM
Jun 1, 2026 11:00AM
Jun 1, 2026 11:00AM
May 14, 2026 09:15AM A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
May 5, 2026 06:00AM
Apr 30, 2026 06:01AM
Apr 30, 2026 06:00AM
Apr 13, 2026 01:29PM
Apr 13, 2026 06:00AM
Apr 13, 2026 06:00AM
Mar 23, 2026 04:56AM Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens Ahead of mPFS Data
Feb 17, 2026 06:00AM
Feb 6, 2026 04:45AM
Jan 11, 2026 12:00PM
Dec 11, 2025 06:00AM
Dec 11, 2025 06:00AM
Dec 10, 2025 06:01AM
Dec 10, 2025 06:00AM IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
Dec 4, 2025 07:00PM
Dec 1, 2025 06:00AM
Dec 1, 2025 06:00AM
Nov 4, 2025 06:00AM
Oct 20, 2025 06:30AM
Oct 20, 2025 06:30AM
Oct 7, 2025 07:53AM Citizens stays bullish on Ideaya ahead of ESMO update
Sep 11, 2025 08:18AM
Sep 8, 2025 08:00AM
Sep 8, 2025 08:00AM
Sep 3, 2025 06:00AM
Sep 3, 2025 06:00AM
Sep 2, 2025 06:01AM
Sep 2, 2025 06:00AM Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Aug 5, 2025 06:00AM
Jul 24, 2025 09:25AM
Jul 24, 2025 09:25AM
May 6, 2025 06:05AM
May 6, 2025 06:01AM
May 6, 2025 06:00AM
Apr 14, 2025 06:00AM IDEAYA Biosciences (IDYA) Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib
Apr 14, 2025 06:00AM
Mar 31, 2025 06:29AM
Mar 31, 2025 06:00AM
Feb 13, 2025 06:05AM
Jan 2, 2025 04:00PM
Dec 21, 2024 10:00AM
Dec 17, 2024 06:00AM IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
Dec 16, 2024 06:04AM

334,268 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All